TIS went the device route as it is easier with a CE mark (look at Oncosil's comments re CE and FDA)...
Presumably there are other benefits to a pharmaceutical classification
If you think about Behrenbruch's blog, and his broad positive and negative comments... then lets think about the board appointing him.
They clearly discussed his public comments and clearly accepted his explanations and the way forward...Isn't that the key of interviewing someone for a job. What can you bring to the company ?
TIS Price at posting:
6.0¢ Sentiment: Buy Disclosure: Held
